PhenoSwitch Chooses Science Exchange as the Primary Online Channel to Offer LC-MS/MS Proteomics Services to Scientists

March 19, 2018 | Posted by Team in News |

PhenoSwitch Bioscience Science ExchangePALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with PhenoSwitch Bioscience to offer online access to its mass spectrometry (LC-MS/MS) services, including SWATH™ proteomics offerings to scientists around the globe.

PhenoSwitch Bioscience is a Quebec, Canada-based contract research organization (CRO) whose mission is to help scientists elevate their research projects with innovative mass spectrometry solutions, in a collaborative manner.

“We are proud to team up with Science Exchange as we share similar philosophies: giving scientists quick and easy access to quality science,” says Hugo Gagnon, Ph.D., CEO and co-founder of PhenoSwitch Bioscience. “Our continuous internal mission to optimize our workflows, attentive listening to our client’s needs and careful scientific revisions are the keys to our success when offering complex services like LC-MS/MS and SWATH™ omics. Moreover, being a small, multidisciplinary scientific team allows us to be flexible and able to accommodate custom requests.”

“We are excited to collaborate with PhenoSwitch Bioscience to make its mass spectrometry services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is heartily committed to adding innovative and qualified providers to our platform, giving scientists quick access to a comprehensive selection of research services. PhenoSwitch Bioscience met our rigorous qualification criteria while demonstrating breakthrough discoveries in the field of drug development, biomarker discovery and fundamental science.”

About PhenoSwitch Bioscience

PhenoSwitch Bioscience Inc. was established in 2013 with the goal of providing expert services in mass spectrometry to major actors in the life science research industry. Today, PhenoSwitch uses the 20+ years of combined life science research experience of its Ph.D. level scientists to help solve research and/or drug discovery problems with modern mass spectrometry approaches. Our team’s commitment and in-depth understanding of mass spectrometry brought us among the world’s leaders in SWATH™ omics technology. We have also grown a unique expertise in the development of high sensitivity micro-flow LC-MS/MS methods. Apart from our proteomics, lipidomics and metabolomics services, we also offer several pre-developed targeted quantitative panels as well as custom methods development for small and large molecules bioanalysis in complex matrices. Follow the company on Twitter @PhenoSwitch.

Interested in learning more about PhenoSwitch Bioscience’s technologies? Request a quote to receive information:

PhenoVista Chooses Science Exchange as the Primary Online Channel to Offer Phenotypic Assays to Scientists

March 12, 2018 | Posted by Team in News |

PhenoVista Partners with Science Exchange

PALO ALTO, CA, March 12, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with PhenoVista Biosciences to offer online access to its Phenotypic Assay Development Services to scientists around the globe.

“Science Exchange has been a steadfast ally of ours since we founded PhenoVista back in 2014. They have always understood the strength of our quantitative imaging-based approach and immediately recognized the great strides our scientists make to deliver the highest quality data possible. We’re very excited about taking our relationship with Science Exchange to the next level and look forward to working with new groups of scientists across the globe.” says James G. Evans, Ph.D., CEO and Founder of PhenoVista Biosciences. PhenoVista Biosciences is a San Diego, California-based CRO and is the leading provider of custom phenotypic assay services. The company’s mission is to enrich the drug discovery community with high-quality information derived from physiologically relevant cell models. PhenoVista specializes in custom assay development in a wide range of therapeutic areas, including CNS, immuno-oncology, and rare diseases.

“We’re delighted to strengthen our partnership with PhenoVista to ensure that their cutting-edge assay services can be made more easily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified providers to our platform, so scientists have the secure services they need readily available to aid their discoveries.  PhenoVista met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of phenotypic assays.”

About PhenoVista Biosciences

PhenoVista is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically-driven project design and management approach, PhenoVista has a proven track record of delivering high quality data from robust and scalable assays. A key advantage that PhenoVista leverages is the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems, with cutting-edge quantitative imaging to deliver clear, actionable output data. PhenoVista’s clients include the majority of top-20 pharmaceutical companies as well as numerous VC-funded biotechnology start-ups. PhenoVista was founded by Dr. James G. Evans and Dr. Anthony Essex in 2014. A privately funded and revenue-driven company, PhenoVista continues to see double-digit revenue growth year over year.

 

Connect with the PhenoVista team by requesting a quote on their storefront today!

Webinar: Re-Writing the Genome

March 12, 2018 | Posted by Team in Webinar |

Combining Gene Editing and iPSC Technologies
for Preclinical Discovery and Translational Research

Watch our webinar on-demand to hear Ruby Chen-Tsai, Ph.D., CSO of Applied StemCell, discuss how her team is using genome engineering and iPSC technologies to advance disease modeling, lead compound discovery, and bioproduction.


You will learn about:

  • Using genome engineering technologies for the generation of preclinical research models
  • How genome editing technologies can be applied to the development of cell and gene therapies
  • Application of gene editing to bioproduction
  • CRISPR-mediated gene editing for the development of nucleic acid reference standards

About Our Speaker

Ruby Yanru Chen-Tsai, Ph.D. has worked on the development and modification of stem cells and pre-clinical models for over 25 years. Prior to Applied StemCell, Dr. Chen-Tsai was at Stanford University, where she served as Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and the “DICE” platform for site-specific gene insertion. Her current research focuses on pre-clinical model development, as well as gene- and stem cell-based therapies using genome editing technologies including CRISPR/Cas9 and TARGATT™ integrase.

CARE Research, LLC Chooses Science Exchange as the Primary Online Channel to Offer Preclinical In Vivo Services to Scientists

March 6, 2018 | Posted by Team in News |

CARE Research on Science Exchange

PALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a partnership with CARE Research, LLC to offer online access to its preclinical services to scientists around the globe.

CARE Research, LLC is a Colorado-based contract research organization (CRO) and a foremost provider of preclinical research. The company’s mission is to deliver services that are competitively priced, of superior quality, and rendered with a high degree of responsiveness that ensures ease of FDA approval.

“Our partnership with Science Exchange allows us to widen our operational reach and to find clients we wouldn’t have connected with had we only used our internal resources,” said Rajan Bawa, Ph.D., co-founder and CEO of CARE Research, LLC. “Additionally, the project managers with whom we have interacted are very responsive, helpful and easily available to answer any questions and facilitate sponsor interactions.”

“We are excited to partner with CARE Research, LLC to make its preclinical in vivo services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is steadfastly committed to adding new innovative and qualified providers to our platform, so scientists have quick access to a breadth of research services. CARE Research, LLC met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of in vivo research.”

About CARE Research, LLC

CARE Research, LLC is a leader in customized preclinical studies with quick turnaround, competitive costing and humane animal handling procedures under strict regulatory compliance. Our experienced, hands-on scientists design and conduct studies that facilitate regulatory approval. Our studies enable both large and small life science companies to achieve their design and exploration goals as well as obtain marketing approval. Our services include a wide range: PK/ MTD, DART, toxicology, IND/NDA enabling studies for drugs and biomedical devices. Our clinical pathology and histopathology capabilities afford a single point of control to our study sponsors. We offer a variety of animal models including rodents, rabbits, dogs, guinea pigs, pigs, mini pigs, goats, sheep, cattle, and horses.  

Need animal studies? Submit your preclinical study scope of work to receive a quote from the CARE Research team:

Tech Q&A with CARE Research

February 12, 2018 | Posted by Team in Provider Spotlight |


 

Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects.

CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you tell us your company’s story?

RB: Twenty years ago, I started this histopathology company, Colorado Histo-Prep. In 2010, we acquired one of our preclinical CRO clients, which was CARE Research, enabling us to provide a one-stop-shop for our clients in the preclinical space.

CD: What capabilities does CARE Research have that set the company apart from other preclinical CROs?

RB: One differentiator is our ability to start projects very swiftly, with quick IACUC approval. We have extensive technical and regulatory experience.

Also, our responsiveness to our sponsor needs, being proactive in providing ongoing progress reports — we don’t wait until things go wrong.

We’re relatively small — we have about 20 people — but that means that we have high-ranking people in our organization — say, VP of Toxicology, or IACUC chairs — actively involved in projects. In large preclinical CROs, very often, there’s a study director who sits in his office, doesn’t even make it to the lab until the sponsor comes to visit.

CD: What preclinical services do you offer that are differentiated from other service providers?

RB: One area of strength is in DART (Developmental and reproductive toxicology) studies and ocular studies. DART services are not often offered by small or medium CROs, because they lack the expertise to carry out these specialized studies.

Ocular studies are another of our core competencies — these are also complex studies, you really have to know what you’re doing.

CD: What type of certifications does CARE Research hold?

RB: That’s a great question. We are OLA certified, AAALAC accredited, and we are GLP. We’re inspected regularly by FDA and USDA.

CD: What types of clients do you serve?

RB: We have a mix of different sponsors. We have large pharma, small biomedical companies, university researchers, startup companies.

In addition to our flexibility and ability to respond quickly, we have the ability to do very complex projects, especially in the surgical and ocular area in contrast to other CROs who may stay away from complex studies.

CD: Finally, could you describe your experience with Science Exchange?

RB: Science Exchange allows us to widen our reach, and allows us to find clients we would not have found using our internal resources. Also, the project managers whom I’ve interacted with are very helpful and responsive, and easily available to answer any questions, provide clarifications, etc in a patient manner.

 

Request a quote from CARE Research and get on the fastest path to completing your preclinical studies.

request quotes button

 

Tech Q&A with Likarda, LLC

February 5, 2018 | Posted by Team in Provider Spotlight |


Guru Singh, Director of Scientific Content, recently spoke with Dr. Lisa Stehno-Bittel, President and Founder of Likarda LLC, an exciting biotech service company on the Science Exchange network.


GS: Nice to meet you, Lisa! Why do clients come to Likarda?

LSB: Likarda is the company you come to when your scientific questions require complex solutions. Our scientists work to create and validate novel assays on a number of different projects, in a timely and efficient manner.

GS: What capabilities does Likarda have that differentiate the company from other service providers and cell-based assay experts?

LSB: We have a strong portfolio of platform technologies that allow us to conduct assays that just aren’t available at other companies. First of all, we have a series of patents around generating, in a high throughput manner, 3D spheroids for drug screening, efficacy testing, toxicity testing, etc. Our Likarda CC Microplate is made using standard plate formats, but in each well of a 384-well plate are 150 different single microwells, in each of which we can grow a different spheroid. That way, we can reduce the number of replicates, saving time and money for the client.

GS: There are many different plate-based models on the market — organoplates, microfluidic chips, etc. — How do Likarda’s plates compare?

LSB: The difference is that Likarda’s plates are really made for a high throughput format and are ideal for complex experiments, for example, when you need to work with multi-cell-type 3D cultures, in an as natural environment as possible. Most of the time, we don’t use any sort of gel or matrix for the 3D cultures — the plates are low-adherence, so the cells stick to each other and not to the plate. This makes the plates easy to work with. We do have a patented hydrogel technology which allows us to make microencapsulated cells using biocompatible materials. We are the first to use these materials for microencapsulation. Microplates and hydrogel — these two technologies really set us apart.

GS: Very cool. How would you describe Likarda’s team?

LSB: All of our scientists have advanced Masters’ degrees in biology or physiology or PhD’s in physiology or bioengineering. We’re a relatively small team, so everyone is involved and gives input into these complex studies that we typically do.

GS: Your clients seem very diverse!

LSB: Yes! Our clients are in the pharmaceutical and nutraceutical industries, as well as food supplements and hygiene. We do work for multinational companies as well as smaller startups.

GS: How has Likarda grown over the years? What lies in the future?

LSB: We started Likarda 5 years ago with money from family and friends. Within 17 months, we were revenue-positive! We’re revenue-driven, and we’re working also on our own products — microplates, hydrogel, regenerative medicine therapies we’re getting ready to take to market.

GS: Can you talk about Likarda’s certifications?

LSB: We’re a woman-owned company, we have the capability to run GLP studies, and we can maintain GMP status for drug development projects, we have continual environmental monitoring.

GS: So, I take it, Likarda has had a successful experience being part of the Science Exchange network.

LSB: Definitely — Science Exchange has been wonderful to work with! With Science Exchange, you have a sourcing agent assigned to you from the very start. That person really does a good job of figuring out what the client needs, and matching them to the right CRO for their research.

Connect with the Likarda team to discuss your project today by visiting www.scienceexchange.com/labs/likarda-llc.

Lab Profile: IBT Bioservices – Personalized Contract Research

March 31, 2014 | Posted by Tess Mayall in Provider Spotlight |

 ibt1

Recently I spoke with Dr. Aman and Todd Pelham at IBT Bioservices, I was blown away by the care and consideration they put into their work.

IBT Bioservices is an early stage drug discovery company that knows the research process doesn’t always go as expected. The lab work isn’t simple; it’s filled twists and turns along the way. As a result, IBT Bioservices is a new version of CRO that has increased expertise and communication to navigate all the bumps in the road.

IBT Bioservices is dedicated to infectious disease research. With expertise in immunology, virology, bacteriology, and animal model development, they’ve established a core of services focused on adding value to early R&D programs. Read the rest of this entry »

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com